FDA approves Afinitor for GI or lung neuroendocrine tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved Afinitor (everolimus), sponsored by Novartis, for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors of gastrointestinal or lung origin with unresectable, locally advanced or metastatic disease. The approval was based on demonstration of improvement in progression-free survival in a multicenter, randomized, placebo-controlled trial of everolimus 10 mg orally once daily...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login